Genmab A/S (Genmab A/S) Price-to-Operating-Cash-Flow

: 17.62 (As of Today)

View and export this data going back to . Start your Free Trial

As of today (2024-04-19), Genmab A/S's share price is $284.55. Genmab A/S's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $16.15. Hence, Genmab A/S's Price-to-Operating-Cash-Flow Ratio for today is 17.62.

The historical rank and industry rank for Genmab A/S's Price-to-Operating-Cash-Flow or its related term are showing as below:

GNMSF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 17 Med: 63.44 Max: 1518.89
Current: 17.67

During the past 13 years, Genmab A/S's highest Price-to-Operating-Cash-Flow Ratio was 1518.89. The lowest was 17.00. And the median was 63.44.

GNMSF's Price-to-Operating-Cash-Flow is ranked better than
61.84% of 283 companies
in the Biotechnology industry
Industry Median: 24.39 vs GNMSF: 17.67

Genmab A/S's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $3.70. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $16.15.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Genmab A/S was 88.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 39.70% per year.

During the past 13 years, Genmab A/S's highest 3-Year average Operating Cash Flow per Share Growth Rate was 122.70% per year. The lowest was -19.90% per year. And the median was 24.40% per year.

Genmab A/S Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Genmab A/S's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

71.10

25.23

77.96

49.63

19.25

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																49.63	26.04	28.19	27.09	19.25

Competitive Comparison

For the Biotechnology subindustry, Genmab A/S's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab A/S Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Genmab A/S's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Price-to-Operating-Cash-Flow falls into.

Genmab A/S Price-to-Operating-Cash-Flow Calculation

Genmab A/S's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	284.55	/	16.145
	=	17.62

Genmab A/S's Share Price of today is $284.55.
Genmab A/S's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.15.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Genmab A/S Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.